Trintellix to Face 4.3% Price Cut under CEA Scheme, No Change for Coralan

Japan’s key reimbursement policy panel on August 4 agreed to apply a 4.3% downward price adjustment for Takeda Pharmaceutical’s antidepressant Trintellix (vortioxetine) under the cost-effectiveness assessment (CEA) system. The Central Social Insurance Medical Council, better known as Chuikyo, approved the...read more